Literature DB >> 33091194

Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom.

Alejandro Arana1, Andrea V Margulis1, Cristina Varas-Lorenzo1, Christine L Bui2, Alicia Gilsenan2, Lisa J McQuay2, Maria Reynolds3, Cristina Rebordosa1, Billy Franks4, Stefan de Vogel4, Kwame Appenteng5, Susana Perez-Gutthann1.   

Abstract

PURPOSE: Strategies to identify and validate acute myocardial infarction (AMI) and stroke in primary-care electronic records may impact effect measures, but to an unknown extent. Additionally, the validity of cardiovascular risk factors that could act as confounders in studies on those endpoints has not been thoroughly assessed in the United Kingdom Clinical Practice Research Datalink's (CPRD's) GOLD database. We explored the validity of algorithms to identify cardiovascular outcomes and risk factors and evaluated different outcome-identification strategies using these algorithms for estimation of adjusted incidence rate ratios (IRRs).
METHODS: First, we identified AMI, stroke, smoking, obesity, and menopausal status in a cohort treated for overactive bladder by applying computerized algorithms to primary care medical records (2004-2012). We validated these cardiovascular outcomes and risk factors with physician questionnaires (gold standard for this analysis). Second, we estimated IRRs for AMI and stroke using algorithm-identified and questionnaire-confirmed cases, comparing these with IRRs from cases identified through linkage with hospitalization/mortality data (best estimate).
RESULTS: For AMI, the algorithm's positive predictive value (PPV) was >90%. Initial algorithms for stroke performed less well because of inclusion of codes for prevalent stroke; algorithm refinement increased PPV to 80% but decreased sensitivity by 20%. Algorithms for smoking and obesity were considered valid. IRRs based on questionnaire-confirmed cases only were closer to IRRs estimated from hospitalization/mortality data than IRRs from algorithm-identified cases.
CONCLUSIONS: AMI, stroke, smoking, obesity, and postmenopausal status can be accurately identified in CPRD. Physician questionnaire-validated AMI and stroke cases yield IRRs closest to the best estimate.
© 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute myocardial infarction; electronic record; information bias; menopause; obesity; pharmacoepidemiology; smoking; stroke; validity

Year:  2020        PMID: 33091194      PMCID: PMC7821285          DOI: 10.1002/pds.5150

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  15 in total

1.  Agreement between GPRD smoking data: a survey of general practitioners and a population-based survey.

Authors:  James D Lewis; Colleen Brensinger
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-07       Impact factor: 2.890

2.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis
Journal:  Circulation       Date:  2012-08-24       Impact factor: 29.690

3.  Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.

Authors:  Andrea V Margulis; Jesper Hallas; Anton Pottegård; Nina Sahlertz Kristiansen; Willem Jan Atsma; Billy Franks; Milbhor D'Silva; Cristina Varas-Lorenzo; Susana Perez-Gutthann; Alejandro Arana
Journal:  Eur J Clin Pharmacol       Date:  2017-11-13       Impact factor: 2.953

4.  Proposal for a universal definition of cerebral infarction.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2008-08-14       Impact factor: 7.914

Review 5.  Six persistent research misconceptions.

Authors:  Kenneth J Rothman
Journal:  J Gen Intern Med       Date:  2014-01-23       Impact factor: 5.128

6.  Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.

Authors:  Andrea V Margulis; Marie Linder; Alejandro Arana; Anton Pottegård; Ina Anveden Berglind; Christine L Bui; Nina Sahlertz Kristiansen; Shahram Bahmanyar; Lisa J McQuay; Willem Jan Atsma; Kwame Appenteng; Milbhor D'Silva; Susana Perez-Gutthann; Jesper Hallas
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

7.  Approach to record linkage of primary care data from Clinical Practice Research Datalink to other health-related patient data: overview and implications.

Authors:  Shivani Padmanabhan; Lucy Carty; Ellen Cameron; Rebecca E Ghosh; Rachael Williams; Helen Strongman
Journal:  Eur J Epidemiol       Date:  2018-09-15       Impact factor: 8.082

8.  Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD).

Authors:  Krishnan Bhaskaran; Harriet J Forbes; Ian Douglas; David A Leon; Liam Smeeth
Journal:  BMJ Open       Date:  2013-09-13       Impact factor: 2.692

9.  Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study.

Authors:  Emily Herrett; Anoop Dinesh Shah; Rachael Boggon; Spiros Denaxas; Liam Smeeth; Tjeerd van Staa; Adam Timmis; Harry Hemingway
Journal:  BMJ       Date:  2013-05-20

10.  Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom.

Authors:  Alejandro Arana; Andrea V Margulis; Cristina Varas-Lorenzo; Christine L Bui; Alicia Gilsenan; Lisa J McQuay; Maria Reynolds; Cristina Rebordosa; Billy Franks; Stefan de Vogel; Kwame Appenteng; Susana Perez-Gutthann
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-10-28       Impact factor: 2.890

View more
  5 in total

1.  Facilitating safety evaluation in maternal immunization trials: a retrospective cohort study to assess pregnancy outcomes and events of interest in low-risk pregnancies in England.

Authors:  Megan Riley; Dimitra Lambrelli; Sophie Graham; Ouzama Henry; Andrea Sutherland; Alexander Schmidt; Nicola Sawalhi-Leckenby; Robert Donaldson; Sonia K Stoszek
Journal:  BMC Pregnancy Childbirth       Date:  2022-06-01       Impact factor: 3.105

2.  Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride.

Authors:  Ana Ruigómez; Estel Plana; Alicia Gilsenan; Joan Fortuny; Miguel Cainzos-Achirica; Robert W V Flynn; Thomas M MacDonald; Luis Garcia-Rodriguez; Ryan Ziemiecki; Elizabeth B Andrews
Journal:  Drug Saf       Date:  2021-02-19       Impact factor: 5.606

3.  Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.

Authors:  Cristina Rebordosa; Estel Plana; Annalisa Rubino; Jaume Aguado; David Martinez; Alejhandra Lei; Sami Daoud; Nuria Saigi-Morgui; Susana Perez-Gutthann; Elena Rivero-Ferrer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-08-02

4.  Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.

Authors:  Veena Hoffman; Jesper Hallas; Marie Linder; Andrea V Margulis; Brandon T Suehs; Alejandro Arana; Kelesitse Phiri; Cheryl Enger; Libby Horter; Ingvild Odsbu; Morten Olesen; Susana Perez-Gutthann; Yihua Xu; Nina Sahlertz Kristiansen; Kwame Appenteng; Stefan de Vogel; John D Seeger
Journal:  Drug Saf       Date:  2021-07-08       Impact factor: 5.606

5.  Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom.

Authors:  Alejandro Arana; Andrea V Margulis; Cristina Varas-Lorenzo; Christine L Bui; Alicia Gilsenan; Lisa J McQuay; Maria Reynolds; Cristina Rebordosa; Billy Franks; Stefan de Vogel; Kwame Appenteng; Susana Perez-Gutthann
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-10-28       Impact factor: 2.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.